Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Translational biomarker study for Phase I tocilizumab + gemcitabine/nab-paclitaxel in refractory metastatic pancreatic cancer
jRCT1030200192Phase 1Active, not recruiting
- Sponsor
- Chugai Pharmaceutical Co., Ltd.
- Start
- May 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, single-arm trial of tocilizumab in pancreatic cancer (PC), sponsored by Chugai Pharmaceutical Co., Ltd. Primary endpoints: Suppression of IL-6 signaling (intratumoral pSTAT3 expression), Suppression of desmoplasia (intratumoral alpha-SMA expression) and 1 more. Started May 2019; status: active, not recruiting.
02
Drugs
tocilizumab
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on jRCT1030200192.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1030200192.